Neural innervation stimulates splenic TFF2 to arrest myeloid cell expansion and cancer

Nature Communications

Volumn 7, Issue , 2016, Pages

  Dubeykovskaya, Zina ^a   Si, Yiling ^a   Chen, Xiaowei ^a   Worthley, Daniel L ^a   Renz, Bernhard W ^a,b   Urbanska, Aleksandra M ^a   Hayakawa, Yoku ^a   Xu, Ting ^a   Westphalen, C Benedikt ^a   Dubeykovskiy, Alexander ^a   Chen, Duan ^c   Friedman, Richard A ^a   Asfaha, Samuel ^a   Nagar, Karan ^a   Tailor, Yagnesh ^a   Muthupalani, Sureshkumar ^d   Fox, James G ^d   Kitajewski, Jan ^e   Wang, Timothy C ^a  

^a Columbia University ^*  (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d Massachusetts Institute of Technology   (United States)

^e Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD115 ANTIGEN; CD31 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CONCANAVALIN A; CYCLIN D1; CYCLIN E; CYCLIN E1; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYMPHOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; NITRIC OXIDE; PROGRAMMED DEATH 1 LIGAND 1; REACTIVE OXYGEN METABOLITE; TREFOIL FACTOR 2; TREFOIL PEPTIDE; UNCLASSIFIED DRUG; CXCR4 PROTEIN, MOUSE; CYTOKINE; MUCIN; MUSCLE PROTEIN; PEPTIDE; TFF2 PROTEIN, MOUSE;

BONE; CANCER; CELLS AND CELL COMPONENTS; GENE; GENE EXPRESSION; IMMUNITY; TUMOR;

ACUTE PHASE RESPONSE; ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; COLON CARCINOGENESIS; COLONY FORMING UNIT GM; COLORECTAL CANCER; COLORECTAL CARCINOGENESIS; CONTROLLED STUDY; DENERVATION; DISEASE SEVERITY; DOWN REGULATION; GENE DELETION; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INNERVATION; MEMORY T LYMPHOCYTE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR VOLUME; UPREGULATION; VAGUS NERVE; VIRAL GENE DELIVERY SYSTEM; ADOPTIVE TRANSFER; ANIMAL; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; COLITIS; COLON; COLORECTAL TUMOR; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; NEOPLASM; PATHOLOGY; PERMEABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECRETION (PROCESS); SPLEEN; T LYMPHOCYTE SUBPOPULATION; TRUNCUS VAGOTOMY; VAGUS NERVE STIMULATION; WESTERN BLOTTING;

ADOPTIVE TRANSFER; ANIMALS; BLOTTING, WESTERN; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; COLITIS; COLON; COLORECTAL NEOPLASMS; CYTOKINES; DENERVATION; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUCINS; MUSCLE PROTEINS; MYELOID CELLS; NEOPLASMS; PEPTIDES; PERMEABILITY; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TREFOIL FACTOR-2; VAGOTOMY, TRUNCAL; VAGUS NERVE; VAGUS NERVE STIMULATION;

EID: 84957582223     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10517     Document Type: Article

References (48)

1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA. Cancer. J. Clin. 64, 9-29 (2014).
2. Rhodes, J. M. & Campbell, B. J. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends. Mol. Med. 8, 10-16 (2002).
3. Serafini, P. Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly. Immunol. Res. 57, 172-184 (2013).
4. Marvel, D. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J. Clin. Invest. 13, 1-9 (2015).
5. Rosas-Ballina, M. et al. Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proc. Natl Acad. Sci. USA 105, 11008-11013 (2008).
6. Rosas-Ballina, M. et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science 334, 98-101 (2011).
7. Hanby, A. M. et al. Spasmolytic polypeptide is a major antral peptide: distribution of the trefoil peptides human spasmolytic polypeptide and pS2 in the stomach. Gastroenterology 105, 1110-1116 (1993).
8. Thim, L., Madsen, F. & Poulsen, S. S. Effect of trefoil factors on the viscoelastic properties of mucus gels. Eur. J. Clin. Invest. 32, 519-527 (2002).
9. Kjellev, S., Nexo, E., Thim, L. & Poulsen, S. S. Systemically administered trefoil factors are secreted into the gastric lumen and increase the viscosity of gastric contents. Br. J. Pharmacol. 149, 92-99 (2006).
10. Cook, G. A., Familari, M., Thim, L. & Giraud, A. S. The trefoil peptides TFF2 and TFF3 are expressed in rat lymphoid tissues and participate in the immune response. FEBS Lett. 456, 155-159 (1999).
11. Kurt-Jones, E. A. et al. Trefoil family factor 2 is expressed in murine gastric and immune cells and controls both gastrointestinal inflammation and systemic immune responses. Infect. Immun. 75, 471-480 (2007).
12. Tran, C. P., Cook, G. A., Yeomans, N. D., Thim, L. & Giraud, A. S. Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut 44, 636-642 (1999).
13. Tracey, K. J. Reflex control of immunity. Nat. Rev. Immunol. 9, 418-428 (2009).
14. Farrell, J. J. et al. TFF2/SP-deficient mice show decreased gastric proliferation, increased acid secretion, and increased susceptibility to NSAID injury. J. Clin. Invest. 109, 193-204 (2002).
15. Yang, R. et al. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res. 66, 6807-6815 (2006).
16. Kuang, D. M. et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 206, 1327-1337 (2009).
17. Hyun, Y. S. et al. Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis 33, 931-936 (2012).
18. Wang, K. et al. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity 41, 1052-1063 (2013).
19. Katoh, H. et al. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 24, 631-644 (2013).
20. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
21. Jauch, D. et al. Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice. Gut 60, 1678-1686 (2012).
22. Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G. & Bar-Sagi, D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21, 836-847 (2012).
23. Murphy, A. J. et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J. Clin. Invest. 121, 4138-4149 (2011).
24. Pencheva, N. et al. Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell 151, 1068-1082 (2012).
25. OuYang, L. Y. et al. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. J. Transl. Med. 13, 47 (2015).
26. Dubeykovskaya, Z., Dubeykovskiy, A., Solal-Cohen, J. & Wang, T. C. Secreted trefoil factor 2 activates the CXCR4 receptor in epithelial and lymphocytic cancer cell lines. J. Biol. Chem. 284, 3650-3662 (2009).
27. Xue, L., Aihara, E., Wang, T. C. & Montrose, M. H. Trefoil factor 2 requires Na/H exchanger 2 activity to enhance mouse gastric epithelial repair. J. Biol. Chem. 286, 38375-38382 (2011).
28. Wills-Karp, M. et al. Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection. J. Exp. Med. 209, 607-622 (2012).
29. Orime, K. et al. Trefoil factor 2 promotes cell proliferation in pancreatic beta-cells through CXCR-4-mediated ERK1/2 phosphorylation. Endocrinology 154, 54-64 (2013).
30. Diaz-Montero, C. M. et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58, 49-59 (2009).
31. Sun, H. L. et al. Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J. Gastroenterol. 18, 3303-3309 (2012).
32. Zhang, B. et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS ONE 8, e57114 (2013).
33. Cortez-Retamozo, V. et al. Origins of tumor-associated macrophages and neutrophils. Proc. Natl Acad. Sci. USA 109, 2491-2496 (2012).
34. Swirski, F. K. et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325, 612-616 (2009).
35. Obermajer, N., Muthuswamy, R., Odunsi, K., Edwards, R. P. & Kalinski, P. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 71, 7463-7470 (2011).
36. Graness, A., Chwieralski, C. E., Reinhold, D., Thim, L. & Hoffmann, W. Protein kinase C and ERK activation are required for TFF-peptide-stimulated bronchial epithelial cell migration and tumor necrosis factor-alpha-induced interleukin-6 (IL-6) and IL-8 secretion. J. Biol. Chem. 277, 18440-18446 (2002).
37. Rivat, C. et al. Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3)-and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res. 65, 195-202 (2005).
38. Storesund, T., Hayashi, K., Kolltveit, K. M., Bryne, M. & Schenck, K. Salivary trefoil factor 3 enhances migration of oral keratinocytes. Eur. J. Oral Sci. 116, 135-140 (2008).
39. Kjellev, S. et al. Pharmacokinetics of trefoil peptides and their stability in gastrointestinal contents. Peptides 28, 1197-1206 (2007).
40. Gronbaek, H., Vestergaard, E. M., Hey, H., Nielsen, J. N. & Nexo, E. Serum trefoil factors in patients with inflammatory bowel disease. Digestion 74, 33-39 (2006).
41. Sharan, S. K., Thomason, L. C., Kuznetsov, S. G. & Court, D. L. Recombineering: a homologous recombination-based method of genetic engineering. Nat. Protoc. 4, 206-223 (2009).
42. Liu, F. & Whitton, J. L. Cutting edge: re-evaluating the in vivo cytokine responses of CD8+ T cells during primary and secondary viral infections. J. Immunol. 174, 5936-5940 (2005).
43. Gentleman, R. C. et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004).
44. Ihaka, R. G. R. A language for data analysis and graphics. J. Comp. Graph Stat. 5, 299-314 (1996).
45. Bolstraed, B. M. in Bioinformatocs and Computational Biology Solutions Using R and Bioconductor. (eds Gentlemen, R., Carey, V., Huber, W., Irizarry, R. & Dubuit, S.) 33-47 (Springer, 2005).
46. Wu, Z. & Irizarry, R. A. Preprocessing of oligonucleotide array data. Nat. Biotechnol. 22, 656-658 author reply 658 (2004).
47. Wu, Z. & Irizarry, R. A. Stochastic models inspired by hybridization theory for short oligonucleotide arrays. J. Comput. Biol. 12, 882-893 (2005).
48. Benjamini, Y. & Hochberg, H. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. Royal Stat. Soc. B 57, 289-300 (1995).